The company have advised that they will re-submit a Marketing Authorisation Application in June/July 2017 including a recently completed Phase 3 study (PAC326) “A randomized, Controlled Study of Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Mylofibrosis” and be pursuing a licence for pacritinib from the European Medicines Authority for this indication after the re-submission. Therefore, NICE has decided to suspend this appraisal from its work programme at this point.